MicroRNA-183-5p Inhibits Aggressiveness of Cervical Cancer Cells by Targeting Integrin Subunit Beta 1 (ITGB1)

Wei Zhang*
Mingkai Zhang*
Lantao Liu
Dan Jin
Pengyu Wang
Jing Hu

* These authors contributed equally to this work

Corresponding Author: Jing Hu, e-mail: jinghu_2001@hotmail.com

Source of support: This work was supported by grants from the Department of Science and Technology of Heilongjiang Province of China (H2018067), the Department of Education of Heilongjiang Province of China (2017-KYYWFMY-0660), and the Health and Family Planning Commission of Heilongjiang Province (2017-340, 2013-199)

Background: Accumulating studies demonstrate that microRNAs play crucial roles in multiple processes of cancer progression. Lower levels of miR-183 have been observed in diverse types of tumors but the mechanism and precise function of miR-183-5p in cervical cancer have largely not been investigated.

Material/Methods: The level of miR-183-5p in different cervical cancer cell lines and clinical tissues was detected qRT-PCR assays. Transwell and wound-healing migration assays were conducted to assess the functional roles of miR-183-5p in over-expressing cervical cancer cells in vitro. Rescue assays were carried out to confirm the contribution of integrin subunit Beta 1 (ITGB1) to the aggressiveness of cancer cells regulated by miR-183-5p.

Results: miR-183-5p was reduced in clinical tissues of cervical cancer and cell lines when compared to the normal subjects and normal cervical epithelial cell line, respectively. In addition, over-expression of miR-183-5p markedly inhibited migration and invasion in cervical cancer cells, and increased aggressiveness was observed in miR-183-5p inhibitor transfected cells. Furthermore, the luciferase reporter assays revealed that ITGB1 was the gene directly regulated by miR-183-5p. Notably, a negative association between the ITGB1 and miR-183-5p was found, and the gene expressions of ITGB1 was mediated by miR-183-5p in cervical cancer cells.

Conclusions: miR-183-5p serves as a latent anti-oncogene by targeting the metastasis-promoter gene, ITGB1.

MeSH Keywords: Cell Migration Assays • MicroRNAs • Neoplasm Invasiveness • Uterine Cervical Neoplasms

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/910295
Background

Cervical cancer remains one of the frequently diagnosed cancers among females worldwide [1,2]. Although the clinical outcome of therapy in patients improves through earlier diagnosis, surgical resection, chemotherapy/radiation therapy, the prognosis of advanced disease still remains unsatisfactory [3,4]. The main reason for the death of patients with cervical cancer is cancer progression and metastasis. Hence, the current research investigated the underlying molecular mechanisms that participate in progression of cervical cancer [5].

MicroRNAs (miRNAs), which are small single-stranded RNA molecules, consist of 18–22 nucleotides [6]. Previous studies demonstrated that miRNAs participate in the mediation of cells malignant growth, differentiation, and apoptotic cellular processes. Recently, studies subsequently confirmed that miRNAs are involved in the pathogenesis of various human diseases, including cancer and nervous system diseases [7,8]. Importantly, researchers have also demonstrated that miRNAs are able to regulate tumor formation, invasion, and metastasis by directly binding to the 3’-UTR of the target gene [9]. Moreover, it was reported that miR-183 is related to the metastasis of several cancers, including osteosarcoma and pancreatic neuroendocrine tumor [10,11]. In colorectal cancer, miR-183 is increased in primary colorectal cancer tissue compared to that in the paracarcinoma tissue, and the Wnt/CTNNB1/miR-183 signaling axis might be a promising biomarker for the recurrence and prognosis of colorectal cancer [12]. In addition, miR-183 facilitates the growth of cancer cells through inhibition of FoxO1 in non-small cell lung carcinoma [13]. Although abundant evidence from previous studies indicated the vital roles of miR-183 in diverse cancers, the possible mechanisms of miR-183-5p in metastasis and aggressiveness of cervical neoplasm remain unknown.

Tumor metastasis is one of the major problems in cancer therapy and urgently requires more effective control [14]. Among metastasis-associated genes, integrins mediate cell-cell as well as tumor cell-extracellular matrix crosstalk by exchanging signals across cellular membranes of cancer cells [15]. Integrins are heterodimers consisting of β and α subunits. For example, integrin β1 is a member of the β sub-family, which forms dimers with different α subunits (α1, α2, α3, α4, α5, α6, α7, and αv). Integrin β1 (ITGB1) has vital roles in growth and motility in breast cancer, non-small cell lung cancer, gastric cancer, and liver cancer [16,17]. In esophageal squamous cell carcinoma (ESCC), integrin αvβ1 and αvβ4 are preferentially located at the invasive front of tumor mass as compared to the normal epithelium, and this change is positively correlated with tumor progression [18]. In non-small cell lung carcinoma, miR-134 inhibits the mobility and invasion of tumor cells via modulating ITGB1 [19]. Another study demonstrated that ITGB1 is the potential target of miR-493-5p and that the quantity of ITGB1 is associated with the prognosis of non-small-cell carcinoma [20]. Although a few studies have confirmed that ITGB1 is regulated by several miRNAs in different types of human cancer, the associations between miR-183-5p and ITGB1 in cervical carcinoma are not entirely known.

In the present study, we examined the expression of miR-183-5p in cervical cancer and its relationship with metastasis in patients. The functions of miR-183-5p in cervical cancer cells mobility and invasiveness capability have not been previously investigated. In the present study, we explored the precise roles of miR-183-5p in cervical cancer cells migration and invasion and revealed the potential target of miR-183-5p.

Material and Methods

Cell lines and tissues samples

Cervical cancer cell lines (SiHa, C-33 A, C-4-I, and CaSkii) and the normal cervical epithelial cell line (ECT1/E6E7) were brought from GuangZhou Jennio Biotech Co., Ltd. (Guangzhou, China). Cells were cultured in 1640 or DEME supplemented with 10% FBS at 37°C with 5% CO₂. We collected 43 cases of cervical cancer from patients who underwent surgical resection from February 2002 to November 2016 at Mudanjiang Medical University. The clinical samples were stored in liquid nitrogen following surgical removal from patients. No patients received additional treatment before surgery. Our study was approved by the Ethics Board of Mudanjiang Medical University. All participants provided written informed consent.

Cell transfection

miR-183-5p, miR-control (miR-NC), miR-183-5p inhibitor (miR-183-5p inh), and miR-NC inhibitor (miR-NC inh) were supplied by GenePharma (Shanghai, China). The shRNA target ITGB1 gene was provided by Guangzhou RiboBio (Guangzhou, China). The expression construct of ITGB1 was produced by subcloning PCR amplified full-length of ITGB1 cDNA into pMSCV retrovirus plasmid. The coding sequences of 3’-UTR ITGB1 was amplified by PCR and cloned into pHY-LV-Report 3.1 vectors (GenePharma). The miR-183-5p, miR-NC, miR-183-5p inh, miR-NC inh, and pMSCV retrovirus plasmid were transfected using Lipofectamine® 2000 reagent (Invitrogen).

qRT-PCR assays

RNA was prepared from either cells or tissue samples using Trizol (Invitrogen). To detect the quantity of miR-183-5p, qRT-PCR analysis was used and U6 was used as the control. To assess the level of ITGB1, RNAs were reversely transcribed
using the PrimeScript RT reagent kit (Takara, Dalian, China). cDNAs were augmented using SYBR Premix DimerEraser (Takara, Dalian, China) in the 7900HT system, and the fold change was calculated using $2^{-\Delta\Delta Ct}$ method. GAPDH gene was used as the control.

Wound closure and invasion assay

Cell monolayers were scratched using 10-µl pipette tips to generate wound gaps. After 24 h, the cells migration was photographed and the cell migration distance was measured. Cells were plated into the upper Matrigel invasion chamber (BD Biosciences) in the absence of FBS. Into the lower chamber we added 600 µl medium containing 10% FBS. After 24 h, the bottom cells of the chamber were stained with 1% crystal violet. Invaded cells were counted in 5 randomly selected fields in each well.

Luciferase assays

The 3'-UTR of the ITGB1 segment was amplified by PCR and fused into pHY-LV-Report 3.1 vector. A mixture of pHY-LV-3'-UTR, miR-NC, or miR-183-5p plasmids was co-transfected into the indicated cells using Lipofectamine® 2000 reagent (Invitrogen). Luciferase activity was measured 24 h later using the Dual Luciferase assay system (Promega).

**Figure 1.** miR-183-5p was under-expressed in cervical carcinoma. (A) Microarray analysis results of miRNA in uterine cervix cancer tissues and corresponding control. (B) The expression quantity of miR-183-5p in 4 cervical cancer cell lines (SiHa, C-33 A, C-4-I, and CaSki) and ECT1/E6E7 was analyzed by qRT-PCR. ** $P < 0.01$, compared to ECT1/E6E7 cells. (C) miR-183-5p was reduced in primary cancer samples compared to matched normal tissues, as shown in qRT-PCR results. (D) miR-183-5p in clinical cervical cancer specimens with or without peritoneal metastasis was detected by qRT-PCR. ** $P < 0.01$, compared to non-metastasis.
Figure 2. miR-183-5p inhibited the mobility of cervical carcinoma cells. (A) CaSki and SiHa cells were transfected with miR-183-5p, and its expression was determined using qRT-PCR method. (B) Transwell assays were conducted to detect the effect of miR-183-5p transfection on cells invasion. (C) CaSki and SiHa cells were both transfected with miR-183-5p and wound-healing assay was conducted. (D) Two cervical carcinoma cell lines were transfected with the miR-183-5p mimics, and then its level was determined by qRT-PCR. (E) Transwell assays revealed that the reduction of miR-183-5p increased the invasive abilities of 2 cell lines. (F) Both cervical cancer cells were transfected with miR-183-5p mimics and wound closure analysis was performed. The number of invaded cells was counted. ** P<0.01, compared to control.
miR-183-5p is under-expressed in cervical cancer

To identify the potential miRNAs that were aberrantly expressed in metastatic cervical cancer, we compared the expression pattern of miRNAs between cervical cancers with metastasis vs. cervical cancer without metastasis using the GEO data set GSE102969. The heat map generated using differential genes revealed that miR-183-5p was expressed at remarkably lower levels (fold change=–2.36 and P-value <0.05) in patients with metastasis (Figure 1A). To further assess the quantity of miR-183-5p in disparate cervical cancer cell lines – SiHa, C-33 A, C-4-I, CaSki, and normal cervical epithelial cells (ECT1/E6E7) – were selected for qRT-PCR assays. As displayed in Figure 1B, miR-183-5p was relatively expressed at lower levels in all cancer cell lines as compared to that in the normal cervical epithelial cell line. We collected 43 pairs of cervical cancer samples and normal tissues to conduct future analysis. After qRT-PCR analysis, miR-183-5p was markedly lower in cancer samples in comparison to the matched control tissues (Figure 1C). In addition, based on the clinical progression, miR-183-5p was remarkably lower in patients with metastasis when compared to the patients without metastasis (Figure 1D).

MiR-183-5p regulates the migration and invasion abilities of cervical carcinoma cells in vitro

Previously, the association between alteration of miRNAs and migration and invasion of several cancer cell lines was

**Immunoblotting analysis**

Cell lysates were extracted using RIPA buffer containing protease inhibitors. We fractionated 25 μg lysates by 8% SDS-PAGE and transferred it to the PVDF membranes (Roche). The membranes were subjected to Western blotting assays, and the ECL detection system (Thermo Scientific) was used for signal assessment.

**Statistical analysis**

The data are presented as mean ±SD and P<0.05 was considered a statistically significant difference. Survival was evaluated using the Kaplan-Meier method, and the relationship between ITGB1 and miR-183-5p was evaluated using Pearson’s correlation.
Figure 4. ITGB1 was over-expressed in cervical carcinoma and negatively associated with the miR-183-5p. (A) Expression of ITGB1 in 43 cases of cervical carcinoma specimens and the corresponding control tissues were analyzed using qRT-PCR. ** P<0.01, compared to adjacent tissues. (B) Linear correlation analysis between ITGB1 and miR-183-5p in cervical carcinoma using Spearman's correlation analysis (n=43, R²=0.226; P<0.01). (C) The levels of ITGB1 in 4 cervical carcinoma cell lines were determined by qRT-PCR analysis. ** P<0.01, compared to ECT1/E6E7 cells. (D) Immunohistochemical staining of ITGB1 in normal and cervical cancer tissues.

**This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)**

Zhang W. et al.: MicroRNA-183-5p inhibits aggressiveness of cervical cancer cells by targeting ITGB1 © Med Sci Monit, 2018; 24: 7137-7145

| Relative expression ITGB1 | 0.0 | 0.5 | 1.0 | 1.5 |
|----------------------------|-----|-----|-----|-----|
| Adjacent (43)              | **  |
| Tumor (43)                 |     |

| Relative mRNA expression  |
|--------------------------|
| 0.0                      |
| 0.2                      |
| 0.4                      |
| 0.6                      |
| 0.8                      |
| 1.0                      |

| Adjacent (43) | Tumor (43) |
|---------------|------------|
| **            |            |

**Relative ITGB1 mRNA expression
R²=0.226, P<0.01

| Relative expression ITGB1 | 0.0 | 1.0 | 2.0 |
|----------------------------|-----|-----|-----|
| ECT1/E6E7                 | **  |
| SiHa                      |     |
| C-33A                     | *** |
| C-4-I                     | *** |
| CaSki                     | *** |

**Relative miR-183-5p expression
R²=0.226, P<0.01

Demonstrated, and it was hypothesized that the down-regulation of miR-183-5p was related to invasion ability and mobility in cervical cancer cells. In order to test this hypothesis, CaSki and SiHa cells were transfected with miR-183-5p to generate miR-183-5p over-expression cells. The level of miR-183-5p following 2 cell lines transfection is shown in Figure 2A. Transwell invasion and wound-healing analyses were then conducted. The results suggest that the migration (Figure 2B) and invasion (Figure 2C) capacity of the 2 cell lines that were transfected with miR-183-5p were remarkably lower than in the parent cells. By contrast, CaSki and SiHa cells transfected with miR-183-5p inhibitor (miR-183-5p inh) exhibited less aggressiveness (Figure 2D, 2E). These findings indicate that miR-183-5p affects migratory and invasive abilities of cervical cancer cells.

**ITGB1 is identified as the direct target of miR-183-5p**

miRNAs control the expression of target genes and regulate cancer cellular processes, including growth and metastasis. Therefore, bioinformatics websites, including microRNA.org, TargetScan, and miRTar were selected to predict latent targets of miR-183-5p. Bioinformatics analysis pointed to a putative binding site of miR-183-5p in the 3'-UTR of ITGB1 (Figure 3A). To confirm whether ITGB1 was the direct target of miR-183-5p, the wild-type (WT) (WT-ITGB1-3'UTR) and mutant (MUT) ITGB1 3'-UTR (MUT-ITGB1-3'UTR) were fused to the pHY-LV-Report 3.1 vector downstream of the luciferase reporter gene (Figure 3A). Then, and SiHa and CaSki cells were co-transfected in combination with pHY-LV-Report 3.1 vector and either miR-NC or miR-183-5p. As presented in Figure 3B, the luciferase activity was obviously inhibited in the cells co-transfected with miR-183-5p and WT-ITGB1-3'-UTR compared with the miR-NC group.

**miR-183-5p expression is negatively correlated with ITGB1 levels**

To determine the association between ITGB1 and miR-183-5p, the expression of ITGB1 in 43 cases of cervical cancer tissues was assessed. The levels of ITGB1 were increased in cervical cancer tissues.
miR-183-5p regulates ITGB1 in cervical carcinoma cell lines

To verify the critical roles of miR-183-5p in the expression of ITGB1, qRT-PCR and immunoblotting assays were conducted to measure its level in SiHa and CaSkı cells transfected with miR-183-5p or miR-183-5p<sup>inh</sup>. The results indicated that up-regulation of miR-183-5p boosted the expression of ITGB1 in SiHa and CaSkı cells (Figure 5A, 5B). By contrast, remarkable suppression of ITGB1 was noticed in the 2 cervical carcinoma cell lines transfected with miR-183-5p<sup>inh</sup> compared to miR-NC-treated cells (Figure 5C, 5D).

MiR-183-5p inhibits aggressiveness of cervical cancer cells via targeting ITGB1

Considering the aforementioned data, whether ITGB1 is the target of miR-183-5p, which affects cellular mobility and invasion, was further investigated. CaSkı and SiHa cells were simultaneously co-transfected in combination pMSCV-ITGB1 with miR-183-5p, and ITGB1 was measured by qRT-PCR (Figure 6A). Then, Transwell and wound-healing assays were conducted. As shown in Figure 6B, 6C, knock-down of ITGB1 significantly neutralized the mobility and invasiveness of CaSkı and SiHa cells. Moreover, these cells were co-transfected with shITGB1 and miR-183-5p<sup>inh</sup>, and ITGB1 was measured using qRT-PCR.
assays (Figure 6D). When ITGB1 expression was restored, it was able to rescue the migration and invasion that was inhibited by miR-183-5p transfected in SiHa and CaSki cells (Figure 6E, 6F). Together, these findings confirm that miR-183-5p affects the aggressiveness of cervical cancer cells via regulating ITGB1.

**Discussion**

In the present study, we found that miR-183-5p acts as an anti-oncogene in cervical carcinoma and that low expression of miR-183-5p is a risk factor for metastasis in patients with cervical cancer. In cervical cancer cells, high levels of miR-183-5p suppressed cellular invasiveness and migration. Furthermore,
ITGB1 was demonstrated to be a potential novel target gene of miR-183-5p, and importantly, ITGB1 was negatively associated with miR-183-5p in cervical cancer tissues.

It has been hypothesized that miRNAs function as either tumor promoters or tumor suppressors, and thus perform vital roles in malignant tumor development and progression [21]. miR-183 acts as a tumor suppressor in osteosarcoma cells by inhibiting the LRP6-Wnt/β-catenin signaling axis [11]. miR-183 is down-regulated in nasopharyngeal carcinoma spheroids and acts as a tumor suppressor. Additional, pheochromocytomas patients with low levels of miR-183 exhibit a better survival rate and miR-183 regulates cellular apoptosis and growth in tongue squamous cell carcinoma cells [22]. From these data, it may be inferred that miR-183-5p is a potential cancer suppressor gene. However, the relationship between miR-183-5p and cervical cancer has not been thoroughly investigated. In the present study, we observed that there was a low level of miR-183-5p in tumor tissues obtained from patients with cervical cancer as compared to matched normal tissues. In addition, miR-183-5p was negatively associated with metastasis.

In vitro experiments demonstrated that up-regulation of miR-183-5p suppressed the mobility and aggressiveness in cervical cancer cells. As part of the present study on how alternation of miR-183-5p affected cells aggressiveness, it was confirmed that ITGB1 is the downstream target of miR-183-5p. Previous studies proved that miRNAs negatively control protein expression through binding to the 3’-UTR of target genes [23]. In our study, luciferase reporter analysis suggested that miR-183-5p directly interacts with the 3’-UTR of the ITGB1 gene.

Conclusions

Over-expression of miR-183-5p led to the inhibition of ITGB1, whereas miR-183-5p inhibitor increased the ITGB1 level. Importantly, restoration of ITGB1 counteracted the inhibition of invasion and migration that were inhibited by miR-183-5p in cervical cancer cells. Based on these findings, we hypothesize that miR-183-5p and ITGB1 have pivotal roles in cervical cancer. In conclusion, we identified miR-183-5p as a promising tumor suppressor in cervical carcinoma; therefore, further investigations of the miR-183-5p/ITGB1 axis may provide a foundation for developing novel potential therapeutic strategies for cervical cancer.

References:

1. Li J, Ping Z, Ning H: MiR-218 impairs tumor growth and increases chemosensitivity to cisplatin in cervical cancer. Int J Mol Sci, 2012; 13: 16053–64
2. Song B, Ding C, Chen W et al: Incidence and mortality of cervical cancer in China, 2013. Chin J Cancer Res, 2017; 29: 471–76
3. Xu H, Yuan Y, Wu W et al: Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin alphavbeta3/FAK/P13K pathway-mediated Rac1 activation. J Biosci, 2017; 42: 491–99
4. Zhao J, Li B, Shu C et al: Downregulation of miR-30a is associated with proliferation and invasion via targeting MIF2D in cervical cancer. Oncol Lett, 2017; 14: 7437–42
5. Karim S, Souho T, Benlemlih M et al: Cervical cancer induction enhancement potential of chlamydia trachomatis: a systematic review. Curr Microbiol, 2018 [Epub ahead of print]
6. Liu Z, Wang C, Jiao X et al: miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NFkappaB. Am J Transl Res, 2016; 8: 4764–77
7. Zhao X, Sun Z, Li H et al: MiR-135a-5p modulates biological functions of thyroid carcinoma cells via targeting VCAN 3′-UTR. Cancer Biomark, 2017; 20: 207–16
8. Zhang Y, Yan LX, Wu QN et al: miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res, 2011; 71: 3552–62
9. Wang G, Li Z, Tian N et al: miR-148b-3p inhibits malignant biological behaviors of human glioma cells induced by high HOTAIR expression. Oncol Lett, 2016; 12: 879–86
10. Zhang YY, Feng HM: MEG3 suppresses human pancreatic neuroendocrine tumor cells growth and metastasis by down-regulation of miR-183. Cell Physiol Biochem, 2017; 44: 345–56
11. Yang X, Wang L, Wang Q et al: MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/beta-catenin signaling pathway. Biochem Biophys Res Commun, 2018; 496: 1197–203
12. Chen Y, Song W: Wnt/catenin beta1/microRNA 183 predicts recurrence and prognosis of patients with colorectal cancer. Oncol Lett, 2018; 15: 4451–56
13. Zhang L, Quan H, Wang S et al: MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol, 2015; 36: 8121–26
14. Zhao YJ, Liu ZZ, Wan S et al: Enhanced expression of SRP22 contributes to aggressive progression and metastasis in prostate cancer. Biomed Pharmacother, 2018; 102: 531–38
15. Singh C, Shyanti RK, Singh V et al: InTEGRIN expression and glycosylation patterns regulate cell-matrix adhesion and alter with breast cancer progression. Biochem Biophys Res Commun, 2018; 492(2): 374–80
16. Pan B, Guo J, Liao Q et al: beta1 and beta3 integrins in breast, prostate and pancreatic cancer: A novel implication. Oncol Lett, 2018; 15: 5412–16
17. Yan P, Zhu H, Yin L et al: Integrin alphavbeta6 promotes lung cancer proliferation and metastasis through upregulation of IL-8-mediated MAPK/ERK signaling. Transl Oncol, 2018; 11: 619–27
18. Vay C, Hosch SB, Stoecklein NH et al: Integrin expression in esophageal squamous cell carcinoma: loss of the physiological integrin expression pattern correlates with disease progression. PLoS One, 2014; 9: e109026
19. Qin Q, Wei F, Zhang J et al: miR-134 suppresses the migration and invasion of nonsmall cell lung cancer by targeting ITGB1. Oncol Rep, 2017; 37: 823–30
20. Liang Z, Kong R, He Z et al: High expression of miR-493-5p positively correlates with clinical prognosis of non small cell lung cancer by targeting oncogene ITGB1. Oncotarget, 2017; 8: 47389–99
21. Meng X, Shi B: miR-215 functions as an oncogene in high-grade glioma by regulating retinoblastoma 1. Biotechnol Lett, 2017; 39: 1351–58
22. Yan D, Cai X, Feng Y: miR-183 modulates cell apoptosis and proliferation in tongue squamous cell carcinoma SCC25 Cell Line. Oncol Res, 2016; 24: 399–404
23. Zhong C, Wang K, Liu Y et al: miR-19b controls cardiac fibroblast proliferation and migration. J Cell Mol Med, 2016; 20: 1191–97